Supernus Pharmaceuticals is acquiring Sage Therapeutics for up to $795 million, adding the FDA-approved postpartum depression treatment Zurzuvae to its portfolio. The acquisition follows a series of setbacks for Sage, including rejected indications and significant layoffs. Supernus aims to leverage Zurzuvae's potential growth, addressing an unmet need affecting approximately 500,000 women annually. The deal is expected to close in Q3 2025. Analysts view the transaction as a modest outcome but a positive resolution for Sage.